In this episode of Clinical Trialblazers, host Alberto Grignolo speaks with Dr. Ross Breckenridge, CEO of Arjuna Therapeutics, a company pioneering a novel approach to precision oncology through therapeutic molecular clusters. Dr. Breckenridge shares insights on the cultural differences between academia and industry, the benefits of conducting clinical trials in Europe over the U.S., and the importance of chemistry manufacturing controls (CMC) in drug development.  He also discusses the challenges of raising capital and the critical role of strong leadership to build and foster a resilient and reliable team. 

We hope you enjoyed this week’s episode of Clinical Trialblazers. Please take a moment to rate and review this podcast wherever you listen.

Special thanks to our production partner, Wonder Media Network. Our producer is Brittany Martinez, our editor is Maddy Foley and our production assistant is Joia Putnoi.